The global fondaparinux market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of the market is attributed to the increasing number of patients with chronic diseases and rising geriatric population. The increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disease has led to an increase in demand for anticoagulants such as fondaparinux. Fondaparinux is used for preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing surgery or those who are immobilized due to illness or injury.
The global fondaparinux market by type includes branded drug and generics drug    Â. The branded drug segment accounted for more than 50% share in 2018 owing to its higher price compared with generics drugs which are available at lower prices. However, the generics drugs segment is expected to grow at a faster rate during the forecast period owing to their affordability and availability across various geographies including emerging markets like India and China where branded drugs are not available due to high cost barriers.
The global fondaparinux market by application includes clinics, hospitals, diagnostic centres, ambulatory surgical centres, home care settings among others. Hospitals accounted for more than 50% share in 2018 owing mainly due its higher usage rates among other applications such as clinics which have lower usage rates but offer better convenience for patients who do not need hospitalization or surgery but require treatment with anticoagulants like fondaparinux.
-Fondaparinux is a low molecular weight heparin that has been shown to be more effective than unfractionated heparin in preventing deep vein thrombosis and pulmonary embolism.
-It is used for the prevention of deep vein thrombosis, pulmonary embolism, and recurrence of deep vein thrombosis or pulmonary embolism.
-The drug has been shown to be safe and effective in reducing the risk of DVT, PE, and recurrence of DVT or PE when compared with UFH therapy alone.
Industry Growth Insights published a new data on “Fondaparinux Market”. The research report is titled “Fondaparinux Market research by Types (Branded Drug, Generics Drug ), By Applications (Clinics, Hospitals, Diagnostic centres, Ambulatory Surgical Centres, Home Care Settings), By Players/Companies Pfizer, Bayer Healthcare AG, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, Apotex, Abbott India, Aspen, Bristol, Eisai, WisMed, Kaifeng, Dr. Reddy’s Laboratories, Mylan, Alchemia”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Fondaparinux Market Research Report
By Type
Branded Drug, Generics DrugÂ
By Application
Clinics, Hospitals, Diagnostic centres, Ambulatory Surgical Centres, Home Care Settings
By Companies
Pfizer, Bayer Healthcare AG, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, Apotex, Abbott India, Aspen, Bristol, Eisai, WisMed, Kaifeng, Dr. Reddy’s Laboratories, Mylan, Alchemia
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Fondaparinux Market Report Segments:
The global Fondaparinux market is segmented on the basis of:
Types
Branded Drug, Generics DrugÂ
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinics, Hospitals, Diagnostic centres, Ambulatory Surgical Centres, Home Care Settings
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Bayer Healthcare AG
- GlaxoSmithKline
- Boehringer Ingelheim
- Sanofi
- Apotex
- Abbott India
- Aspen
- Bristol
- Eisai
- WisMed
- Kaifeng
- Dr. Reddy’s Laboratories
- Mylan
- Alchemia
Highlights of The Fondaparinux Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Branded Drug
- Generics DrugÂ
- By Application:
- Clinics
- Hospitals
- Diagnostic centres
- Ambulatory Surgical Centres
- Home Care Settings
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fondaparinux Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fondaparinux is a medication used to treat venous thromboembolism (VTE). It is a low-molecular-weight heparin. Fondaparinux works by preventing the formation of blood clots.
Some of the key players operating in the fondaparinux market are Pfizer, Bayer Healthcare AG, GlaxoSmithKline, Boehringer Ingelheim, Sanofi, Apotex, Abbott India, Aspen, Bristol, Eisai, WisMed, Kaifeng, Dr. Reddy¢â‚¬â„¢s Laboratories, Mylan, Alchemia.
The fondaparinux market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Fondaparinux Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Fondaparinux Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Fondaparinux Market - Supply Chain
4.5. Global Fondaparinux Market Forecast
4.5.1. Fondaparinux Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Fondaparinux Market Size (000 Units) and Y-o-Y Growth
4.5.3. Fondaparinux Market Absolute $ Opportunity
5. Global Fondaparinux Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Fondaparinux Market Size and Volume Forecast by Type
5.3.1. Branded Drug
5.3.2. Generics Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Fondaparinux Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Fondaparinux Market Size and Volume Forecast by Application
6.3.1. Clinics
6.3.2. Hospitals
6.3.3. Diagnostic centres
6.3.4. Ambulatory Surgical Centres
6.3.5. Home Care Settings
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Fondaparinux Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Fondaparinux Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Fondaparinux Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Fondaparinux Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Fondaparinux Demand Share Forecast, 2019-2026
9. North America Fondaparinux Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Fondaparinux Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Fondaparinux Market Size and Volume Forecast by Application
9.4.1. Clinics
9.4.2. Hospitals
9.4.3. Diagnostic centres
9.4.4. Ambulatory Surgical Centres
9.4.5. Home Care Settings
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Fondaparinux Market Size and Volume Forecast by Type
9.7.1. Branded Drug
9.7.2. Generics Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Fondaparinux Demand Share Forecast, 2019-2026
10. Latin America Fondaparinux Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Fondaparinux Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Fondaparinux Market Size and Volume Forecast by Application
10.4.1. Clinics
10.4.2. Hospitals
10.4.3. Diagnostic centres
10.4.4. Ambulatory Surgical Centres
10.4.5. Home Care Settings
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Fondaparinux Market Size and Volume Forecast by Type
10.7.1. Branded Drug
10.7.2. Generics Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Fondaparinux Demand Share Forecast, 2019-2026
11. Europe Fondaparinux Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Fondaparinux Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Fondaparinux Market Size and Volume Forecast by Application
11.4.1. Clinics
11.4.2. Hospitals
11.4.3. Diagnostic centres
11.4.4. Ambulatory Surgical Centres
11.4.5. Home Care Settings
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Fondaparinux Market Size and Volume Forecast by Type
11.7.1. Branded Drug
11.7.2. Generics Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by ype
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Fondaparinux Demand Share, 2019-2026
12. Asia Pacific Fondaparinux Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Fondaparinux Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Fondaparinux Market Size and Volume Forecast by Application
12.4.1. Clinics
12.4.2. Hospitals
12.4.3. Diagnostic centres
12.4.4. Ambulatory Surgical Centres
12.4.5. Home Care Settings
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Fondaparinux Market Size and Volume Forecast by Type
12.7.1. Branded Drug
12.7.2. Generics Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Fondaparinux Demand Share, 2019-2026
13. Middle East & Africa Fondaparinux Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Fondaparinux Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Fondaparinux Market Size and Volume Forecast by Application
13.4.1. Clinics
13.4.2. Hospitals
13.4.3. Diagnostic centres
13.4.4. Ambulatory Surgical Centres
13.4.5. Home Care Settings
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Fondaparinux Market Size and Volume Forecast by Type
13.7.1. Branded Drug
13.7.2. Generics Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Fondaparinux Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Fondaparinux Market: Market Share Analysis
14.2. Fondaparinux Distributors and Customers
14.3. Fondaparinux Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer Healthcare AG
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Boehringer Ingelheim
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Sanofi
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Apotex
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Abbott India
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Aspen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Bristol
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Eisai
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. WisMed
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Kaifeng
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Dr. Reddys Laboratories
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Mylan
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Alchemia
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
